サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1409540

腫瘍内がん治療の世界市場レポート 2024年

Intratumoral Cancer Therapies Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
腫瘍内がん治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

腫瘍内がん治療の市場規模は近年急速に拡大しています。2023年の1,248億2,000万米ドルから2024年には1,415億5,000万米ドルへと、CAGR13.4％で拡大します。過去の期間に見られた成長は、がん研究の進歩、がん罹患率の上昇、精密医療への需要、臨床エビデンスや研究イニシアティブ、アンメットメディカルニーズによるものと考えられます。

腫瘍内がん治療市場規模は、今後数年で急成長が見込まれます。2028年にはCAGR11.8％で2,214億6,000万米ドルに成長します。予測期間中に予想される成長は、免疫療法の進歩、精密医療の採用の高まり、臨床試験の拡大、希少がんへの注目の高まり、その後の承認による規制当局の支援などに起因すると考えられます。予測期間中に予想される主な動向には、腫瘍内免疫調節薬の探求、画像誘導療法の統合、腫瘍内治療における温熱療法の応用、併用療法の臨床試験の開始、腫瘍内治療に対する規制当局の継続的な支援などが含まれます。

がんの有病率の上昇は、当面の腫瘍内がん治療市場の拡大を牽引すると予想されます。がんは、体内の異常細胞の無秩序な増殖と拡散を特徴とする疾患群です。腫瘍内がん治療は、がん患者の標的外毒性、用量制限毒性、免疫刺激による副作用を軽減することにより、がんの診断と治療において重要な役割を果たしています。例えば、米国を拠点とする非営利のがん擁護団体である米国がん協会（American Cancer Society）は、2023年1月現在、がん罹患者数が195万8310人となり、2021年の189万8160人から3.16％増加すると報告しています。このように、がん罹患数の増加が腫瘍内がん治療市場の成長を促進する重要な要因となっています。

免疫療法の統合が腫瘍内がん治療市場の成長を促進すると期待されています。免疫療法は、がん細胞を識別して破壊するために身体の免疫システムを強化するがん治療法であり、ますます顕著になってきています。腫瘍内治療は、腫瘍微小環境内の免疫反応を調節するための標的化された強力なアプローチを提供し、免疫療法が重視されるようになっていることに合致しています。注目すべきは、2022年6月に米国食品医薬品局（FDA）が35のICIベースの併用免疫療法を承認したことで、免疫療法の統合が進み、腫瘍内がん治療市場に影響を与えていることが強調されています。

北米は、2023年の腫瘍内がん治療市場で最大の地域でした。腫瘍内がん治療市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 腫瘍内がん治療市場の特徴

第3章 腫瘍内がん治療市場の動向と戦略

第4章 腫瘍内がん治療市場- マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の腫瘍内がん治療市場の規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 腫瘍内がん治療市場セグメンテーション

  • 世界の腫瘍内がん治療市場、技術別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • モノクローナル抗体
  • ワクチン
  • チェックポイント阻害剤
  • 細胞療法
  • 免疫システムモジュレーター
  • 養子細胞移植
  • サイトカイン
  • 世界の腫瘍内がん治療市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 肺がん
  • 乳がん
  • メラノーマ
  • 前立腺がん
  • 頭頸部がん
  • その他の用途
  • 世界の腫瘍内がん治療市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • がん研究センター
  • クリニック

第7章 腫瘍内がん治療市場の地域および国分析

  • 世界の腫瘍内がん治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の腫瘍内がん治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋の腫瘍内がん治療市場

第9章 中国の腫瘍内がん治療市場

第10章 インドの腫瘍内がん治療市場

第11章 日本の腫瘍内がん治療市場

第12章 オーストラリアの腫瘍内がん治療市場

第13章 インドネシアの腫瘍内がん治療市場

第14章 韓国の腫瘍内がん治療市場

第15章 西欧の腫瘍内がん治療市場

第16章 英国の腫瘍内がん治療市場

第17章 ドイツの腫瘍内がん治療市場

第18章 フランスの腫瘍内がん治療市場

第19章 イタリアの腫瘍内がん治療市場

第20章 スペインの腫瘍内がん治療市場

第21章 東欧の腫瘍内がん治療市場

第22章 ロシアの腫瘍内がん治療市場

第23章 北米の腫瘍内がん治療市場

第24章 米国の腫瘍内がん治療市場

第25章 カナダの腫瘍内がん治療市場

第26章 南米の腫瘍内がん治療市場

第27章 ブラジルの腫瘍内がん治療市場

第28章 中東の腫瘍内がん治療市場

第29章 アフリカの腫瘍内がん治療市場

第30章 腫瘍内がん治療市場の競合情勢と企業プロファイル

  • 腫瘍内がん治療市場の競合情勢
  • 腫瘍内がん治療市場の企業プロファイル
    • Amgen Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Pfizer Inc.

第31章 世界の腫瘍内がん治療市場の競合ベンチマーキング

第32章 世界の腫瘍内がん治療市場の競争力ダッシュボード

第33章 腫瘍内がん治療市場における主要な合併と買収

第34章 腫瘍内がん治療市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r11078

“Intratumoral Cancer Therapies Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intratumoral cancer therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for intratumoral cancer therapies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The intratumoral cancer therapies market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Technology: Monoclonal Antibodies; Vaccines; Checkpoint Inhibitors; Cell Therapies; Immunes System Modulator; Adoptive Cell Transfer; Cytokines
  • 2) By Application: Lung Cancer; Breast Cancer; Malenoma; Prostate Cancer; Head and Neck Cancer; Other Applications
  • 3) By End Users: Hospitals; Cancer Research Centers; Clinics
  • Companies Mentioned: Amgen Inc.; AstraZeneca plc; Bayer AG; Bristol-Myers Squibb Company; Pfizer Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Intratumoral cancer therapies involve treatments directly administered or applied to a tumor. These therapies are specifically crafted to target tumor cells and can be employed in conjunction with other cancer treatments, such as chemotherapy and radiation therapy.

The primary categories of intratumoral cancer therapies encompass monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, and cytokines. Monoclonal antibodies denote a specific type of artificially created protein capable of binding to particular bodily targets, including antigens present on the surface of cancer cells. They find application in various contexts, such as lung cancer, breast cancer, melanoma, prostate cancer, head and neck cancer, among others, and are utilized by diverse end users, including hospitals, cancer research centers, and clinics.

The intratumoral cancer therapies market research report is one of a series of new reports from The Business Research Company that provides intratumoral cancer therapies market statistics, including intratumoral cancer therapies industry global market size, regional shares, competitors with an intratumoral cancer therapies market share, detailed intratumoral cancer therapies market segments, market trends and opportunities, and any further data you may need to thrive in the intratumoral cancer therapies industry. This intratumoral cancer therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intratumoral cancer therapies market size has grown rapidly in recent years. It will grow from $124.82 billion in 2023 to $141.55 billion in 2024 at a compound annual growth rate (CAGR) of 13.4%. The growth observed in the historical period can be ascribed to advancements in cancer research, a rise in cancer incidence, the demand for precision medicine, clinical evidence and research initiatives, as well as unmet medical needs.

The intratumoral cancer therapies market size is expected to see rapid growth in the next few years. It will grow to $221.46 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The anticipated growth in the forecast period can be attributed to advancements in immunotherapy, a heightened adoption of precision medicine, the expansion of clinical trials, a growing focus on rare cancers, and regulatory support with subsequent approvals. Major trends expected in the forecast period include the exploration of intratumoral immunomodulators, the integration of image-guided therapies, the application of hyperthermia in intratumoral treatments, the initiation of clinical trials for combination therapies, and continued regulatory backing for intratumoral therapies.

The rising prevalence of cancer is anticipated to drive the expansion of the intratumoral cancer therapies market in the foreseeable future. Cancer comprises a group of diseases characterized by the uncontrolled proliferation and dissemination of abnormal cells within the body. Intratumoral cancer therapies play a crucial role in the diagnosis and treatment of cancer by mitigating off-target toxicities, dose-limiting toxicities, and adverse effects resulting from immune stimulation in patients with cancer. For instance, as of January 2023, the American Cancer Society, a nonprofit cancer advocacy organization based in the United States, reported an increase in the number of cancer cases to 1,958,310, representing a growth of 3.16% from 1,898,160 in 2021. This, escalation in cancer incidence is a significant factor propelling the growth of the intratumoral cancer therapies market.

The integration of immunotherapy is expected to fuel the growth of the intratumoral cancer therapies market. Immunotherapy, a cancer treatment that enhances the body's immune system to identify and destroy cancer cells, is becoming increasingly prominent. Intratumoral therapies align with the growing emphasis on immunotherapy, providing a targeted and potent approach to modulating the immune response within the tumor microenvironment. Notably, in June 2022, the United States Food and Drug Administration (FDA) approved 35 ICI-based combination immunotherapies, highlighting the increasing integration of immunotherapy and its impact on the intratumoral cancer therapies market.

Technological advancements emerge as a noteworthy trend in the intratumoral cancer therapies market. Companies in this sector are adopting innovative technologies to maintain their market standing. For instance, in March 2022, Evonik, a US-based specialty chemical manufacturing company, introduced EUDRATEC SoluFlow, a novel microparticle technology designed to enhance the solubility of active medicinal components in oral cancer medication formulations. This breakthrough technology allows previously considered insoluble chemicals to be used in a broader range of oral medications.

In September 2022, CytoReason Ltd, an Israel-based biotechnology company, partnered with Pfizer Inc. to leverage artificial intelligence (AI) for drug discovery and development. Through this collaboration, Pfizer will incorporate CytoReason's AI technologies into its drug research activities, with the agreement valued up to $110 million over the next five years. Pfizer's contribution includes $20 million in stock, options to license CytoReason's platform and disease models, and additional project support. Pfizer Inc., a US-based pharmaceutical company specializing in intestine cancer therapeutics, aims to enhance its drug discovery efforts through this collaboration.

In January 2023, AstraZeneca, a UK-based biopharmaceutical firm focusing on oncology and rare diseases, acquired Neogene Therapeutics Inc. for $120 million. This acquisition expands AstraZeneca's capabilities in cancer treatment by incorporating Neogene Therapeutics Inc., an Amsterdam-based biotechnology research company offering personalized treatments based on TCR genes targeting neoantigens detected in a specific patient's tumor.

Major companies operating in the intratumoral cancer therapies market report are Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-la Roche, Celgene Corporation, Takeda Pharmaceutical Company Ltd., GSK plc, Ziopharm Oncology Inc., Celldex Therapeutics Inc., Astellas Pharma Inc., Sirnaomics, Checkmate Pharmaceuticals Inc., Immunovative Therapies Ltd., Idera Pharmaceuticals Inc., Daiichi Sankyo, Philogen S.p.A., Apexigen Inc., Merck Group, OncoSec Medical Incorporated, DNAtrix, Istari Oncology Inc., Nanobiotix, Exicure Inc., Karyopharm Therapeutics Inc., Dechra Pharmaceuticals PLC, Torigen Pharmaceuticals Inc., Elekta, Virbac, Norbrook Laboratories, Aratana Therapeutics Inc., Regeneus Ltd., QBiotics Group, VetDC, AdvaVet Inc

North America was the largest region in the intratumoral cancer therapies market in 2023. The regions covered in the intratumoral cancer therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the intratumoral cancer therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intratumoral cancer therapies market consists of revenues earned by entities by chemotherapy, radiation therapy, immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Intratumoral Cancer Therapies Market Characteristics

3. Intratumoral Cancer Therapies Market Trends And Strategies

4. Intratumoral Cancer Therapies Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Intratumoral Cancer Therapies Market Size and Growth

  • 5.1. Global Intratumoral Cancer Therapies Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Intratumoral Cancer Therapies Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Intratumoral Cancer Therapies Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Intratumoral Cancer Therapies Market Segmentation

  • 6.1. Global Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Monoclonal Antibodies
  • Vaccines
  • Checkpoint Inhibitors
  • Cell Therapies
  • Immunes System Modulator
  • Adoptive Cell Transfer
  • Cytokines
  • 6.2. Global Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Lung Cancer
  • Breast Cancer
  • Malenoma
  • Prostate Cancer
  • Head and Neck Cancer
  • Other Applications
  • 6.3. Global Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Cancer Research Centres
  • Clinics

7. Intratumoral Cancer Therapies Market Regional And Country Analysis

  • 7.1. Global Intratumoral Cancer Therapies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Intratumoral Cancer Therapies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Intratumoral Cancer Therapies Market

  • 8.1. Asia-Pacific Intratumoral Cancer Therapies Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Intratumoral Cancer Therapies Market

  • 9.1. China Intratumoral Cancer Therapies Market Overview
  • 9.2. China Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Intratumoral Cancer Therapies Market

  • 10.1. India Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Intratumoral Cancer Therapies Market

  • 11.1. Japan Intratumoral Cancer Therapies Market Overview
  • 11.2. Japan Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Intratumoral Cancer Therapies Market

  • 12.1. Australia Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Intratumoral Cancer Therapies Market

  • 13.1. Indonesia Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Intratumoral Cancer Therapies Market

  • 14.1. South Korea Intratumoral Cancer Therapies Market Overview
  • 14.2. South Korea Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Intratumoral Cancer Therapies Market

  • 15.1. Western Europe Intratumoral Cancer Therapies Market Overview
  • 15.2. Western Europe Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Intratumoral Cancer Therapies Market

  • 16.1. UK Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Intratumoral Cancer Therapies Market

  • 17.1. Germany Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Intratumoral Cancer Therapies Market

  • 18.1. France Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Intratumoral Cancer Therapies Market

  • 19.1. Italy Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Intratumoral Cancer Therapies Market

  • 20.1. Spain Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Intratumoral Cancer Therapies Market

  • 21.1. Eastern Europe Intratumoral Cancer Therapies Market Overview
  • 21.2. Eastern Europe Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Intratumoral Cancer Therapies Market

  • 22.1. Russia Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Intratumoral Cancer Therapies Market

  • 23.1. North America Intratumoral Cancer Therapies Market Overview
  • 23.2. North America Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Intratumoral Cancer Therapies Market

  • 24.1. USA Intratumoral Cancer Therapies Market Overview
  • 24.2. USA Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Intratumoral Cancer Therapies Market

  • 25.1. Canada Intratumoral Cancer Therapies Market Overview
  • 25.2. Canada Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Intratumoral Cancer Therapies Market

  • 26.1. South America Intratumoral Cancer Therapies Market Overview
  • 26.2. South America Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Intratumoral Cancer Therapies Market

  • 27.1. Brazil Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Intratumoral Cancer Therapies Market

  • 28.1. Middle East Intratumoral Cancer Therapies Market Overview
  • 28.2. Middle East Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Intratumoral Cancer Therapies Market

  • 29.1. Africa Intratumoral Cancer Therapies Market Overview
  • 29.2. Africa Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Intratumoral Cancer Therapies Market Competitive Landscape And Company Profiles

  • 30.1. Intratumoral Cancer Therapies Market Competitive Landscape
  • 30.2. Intratumoral Cancer Therapies Market Company Profiles
    • 30.2.1. Amgen Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. AstraZeneca plc
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Bayer AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bristol-Myers Squibb Company
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Pfizer Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Intratumoral Cancer Therapies Market Competitive Benchmarking

32. Global Intratumoral Cancer Therapies Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Intratumoral Cancer Therapies Market

34. Intratumoral Cancer Therapies Market Future Outlook and Potential Analysis

  • 34.1 Intratumoral Cancer Therapies Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Intratumoral Cancer Therapies Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Intratumoral Cancer Therapies Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer